【网学提醒】：本文主要为网上学习者提供心肌保护临床研究和应用进展，希望对需要心肌保护临床研究和应用进展网友有所帮助，学习一下吧!
资料包括： 论文(8页6595字)
说明：
【摘要】 心肌保护近年来的发展多注重基础研究紧密联系临床，积极转化为临床实践，心肌保护液的添加成分、减轻炎症反应的策略、缺血预调在临床方面的应用都是学者们高度关注的重要部分，能够转化到临床，成为有效的心肌保护措施。
【关键词】 心肌保护,缺血预调,炎症反应
【Abstract】 Recent years，the development of myocardial protection emphasized in what can provide tight junction between fundamental research and clinical practice.scholars pay highly attention to the elements added to cardioplegia，strategy to reduce inflammatory reaction，the application of ischemic preconditioning in clinical practice，which can be translate into clinical and become efficiently strategy for myocardial protection.
【Key words】 myocardial protection；ischemic preconditioning；inflammatory reaction
尽管心肌保护已经发展了多年，但在急性心梗的治疗及心脏手术的临床应用当中，心肌保护的方法和效果有待于进一步开拓。近年来在心肌保护液的添加成分、控制全身炎症反应、缺血预调等方面有些新的观点及进展，本文就此综述如下。
目录：
1 心肌保护液的进展
2 控制全身炎症反应综合征(SIRS)的策略
3 Na+-H+交换抑制剂
4 心肌缺血预调(ischemic preconditioning，IP)
参考文献：
1 Khandoudi N，Percevault-Albadine J，Bril A.Comparative effects of carvedilol and metoprolol on cardiac ischemia-reperfusion injury.J Cardiovasc Pharmacol，1998，32(3)：443-451.
2 Kuhn-Regnier F，Natour E，Dhein S，et al.Beta-blockade versus Buckberg blood cardioplegia in coronary bypass operation.Eur J Cardiothorac Surg，1999，15(1)：67-74.
3 Bessho R，Chambers DJ.Myocardial protection with oxygenated esmolol cardioplegia during prolonged normothermic ischemia in the rat.J Thorac Cardiovasc Surg，2002，124(2)：340-351.
4 Rao V，Borger MA，Weisel RD，et al.Insulin cardioplegia for elective coronary bypass surgery.J Thorac Cardiovasc Surg，2000，119 (6)：1176-1184.
5 Rao V，Christakis GT，Weisel RD，et al.The Insulin Cardioplegia Trial：myocardial protection for urgent coronary artery bypass grafting.J Thorac Cardiovasc Surg，2002，123(5)：928-935.
6 Engelman DT，Watanabe M，Maulik N，et al.L-arginine reduces endothelial inflammation and myocardial stunning during ischemia/reperfusion.Ann Thorac Surg，1995，60(5)：1275-1281.
7 Mizuno A，Baretti R，Buckberg GD，et al.Endothelial stunning and myocyte recovery after reperfusion of jeopardized muscle：a role of L-arginine blood cardioplegia.J Thorac Cardiovasc Surg，1997，113(2)：379-389.
8 Wallace AW，Ratcliffe MB，Galindez D，et al.L-arginine infusion dilates coronary vasculature in patients undergoing coronary artery bypass surgery.Anesthesiology，1999，90(6)：1577-1586.
9 Carrier M，Pellerin M，Perrault LP，et al.Cardioplegic arrest with L-arginine improves myocardial protection：results of a prospective randomized clinical trial.Ann Thorac Surg，2002，73(3)：837-842.
10 Asimakopoulos G.Mechanisms of the systemic inflammatory response.Perfusion，1999，14(4)：269-277.
11 Giomarelli P，Sabino S，Borrelli E，et al.Myocardial and lung injury after cardiopulmonary bypass：role of interleukin (IL)-10.Ann Thorac Surg，2003，76(1)：117-123.
12 Bach F，Grundmann U，Bauer M，et al.Modulation of the inflammatory response to cardiopulmonary bypass by dopexamine and epidural anesthesia.Acta Anaesthesiol Scand，2002，46(10)：1227-1235.
13 Tayama E，Hayashida N，Fukunaga S，et al.High-dose cimetidine reduces proinflammatory reaction after cardiac surgery with cardiopulmonary bypass.Ann Thorac Surg，2001，72(6)：1945-1949.
14 Brull DJ，Sanders J，Rumley A，et al.Impact of angiotensin converting enzyme inhibition on post-coronary artery bypass interleukin 6 release.Heart，2002，87(3)：252-255.
15 徐康清，孙培吾，黄文起，等.乌司他丁对体外循环心脏手术后肺功能的影响.中华心血管外科杂志，2004，20(1)：7-9.
16 Mojcik CF，Levy JH.Aoprotinin and the systemic inflammatory response after
cardiopulmonary bypasss.Ann Thorac Surg，2001，71(2)：745-754.
17 Li D，Zhao L，Liu M，et al.Kinetics of tumor necrosis factor alpha in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor alpha in acute myocardial infarction.Am Heart J，1999，137(6)：1145-1152.
18 Fitch JC，Rollins S，Matis L，et al.Pharmacology and biological efficacy of a recombinant，humanized，single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass.Circulation，1999，100 (25)：2499-2506.
19 Grossi EA，Kallenbach K，Chau S，et al.Impact of heparin bonding on pediatric cardiopulmonary bypass： a prospective randomized study.Ann Thorac Surg，2000，70(1)：191-196.
20 Palatianos GM，Balentine G，Papadakis EG，et al.Neutrophil depletion reduces myocardial reperfusion morbidity.Ann Thorac Surg，2004，77(3)：956-961.
21 Karaiskos TE，Palatianos GM，Triantafillou CD，et al.Clinical effectiveness of Leukocyte filtration during cardiopulmonary bypass in patients with chronic obstructive pulmonary disease.Ann Thorac Surg，2004，78(4)：1339-1344.
22 Yndaard S，Andersen LW，Andersen C，et al.The effect of modified ultrafiltrution on the amount of circulating endotoxins in children undergoing cardiopulmonary bypass.J cardiothorac Vasc Anesth，2000，14(4)：399-401.
23 Richter JA，Meisner H，Tassani P，et al.Drew-Anderson technique attenuates systemic inflammatory response syndrome and improve s respiratory function after coronary artery bypass grafting.Ann Thorac Surg，2000，69(1)：77-83.
24 Yellon DM，Baxter GF.Sodium-hydrogen exchange in myocardial reperfusion injury.Lancet，2000，356(9229)：522-523.
25 Goldberg SP，Digerness SB，Skinner JL，et al.Ischemic preconditioning and Na+/H+ exchange inhibition improve reperfusion ion homeostasis.Ann Thorac Surg，2002，73(2)：569-574.
26 Theroux P，Chaitman BR，Danchin N，et al.Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations.Main results of the GUARDIAN trial，Guard during ischemia against necrosis (GUARDIAN) Investigators.Circulation，2000，102(25)：3032-3038.
27 Bolli R.The Late Phase of preconditioning.Circ Res，2000，87(11)：972-983.
28 Kallner G，Owall A，Franco-Cereced A，et al.Myocardial outflow CGRP in relation to rnetabollc stress during coronary artery bypass grafting without cardiopulmonary bypass.J Thorac Cardlovasc Surg，1999，117(3)：447-453.
29 Wei M，Kuukasjarvi P，Laurikka J，et al.Cardioprotective effect of adenosine pre-treatment in coronary artery bypass grafting.Chest，2001，120(3)：860-865.
30 Belhomme D，Peynet J，Florens E，et al.Is adenosine preconditioning truly cardioprotective in coronary artery bypass surgery? Ann Thorac Surg，2000，70(2)：590-594.
31 Ross A，Gibbons R，Kloner RA，et al.Acute myocardial infarction study with adenosine (AMISTAD II).J Am Coll Cardiol，2002，39(2 Suppl)：338-340.
32 Marzilli M，Orsini E，Marraccini P，et al.Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction.Circulation，2000，101 (18)：2154-2159.
33 De Hert SG，Cromheecke S，Ten Broecke PW，et al.Sevoflurane but not propofol preserves myocardial function in coronary surgery patients.Anesthesiology，2002，97(1)：42-49.
34 Toller WG，Kersten JR，Gross ER，et al.Isoflurane preconditions myocardium against infarction via activation of inhibitory guanine nucleotide binding proteins.Anesthesiology，2000，92(5)：1400-1407.
35 Karck M，Tanaka S，Bolling SF，et al.Myocardial protection by ischemic preconditioning and δ-opioid receptor activation in the isolated working rat heart.J Thorac Cardiovasc Surg，2001，122(5)：986-992.
36 Liu Y，Sato T，Seharaseyon J，et al.Mitochondrial ATP-dependent potassium channels.Viable candidate effectors of ischemic preconditioning.Ann NY Acad Sci，1999，874：27-37.
37 Kowaltowski AJ，Seetharaman S，Paucek P，et al.Bioenergetic consequences of opening the ATP-sensitive K+ channel of heart mitochondria.Am J Physiol Heart Circ Physiol，2001，280(2)：649-657.
38 Loubani M，Galinanes M.Pharmacological and ischemic preconditioning of the human myocardium：mito KATP channels are upstream and p38MAPK is downstream of PKC.BMC Physiol，2002，2(1)：10-23.
39 O’Rourke B.Evidence for mitochondrial K+ channels and their role in cardioprotection.Circ Res，2004，94(4)：420-432.
40 Zhao ZQ，Vinten-Johansen J.Myocardial apoptosis and ischemic preconditioning.J Cardio Res，2002，55(3)：438-455.
41 Wu ZK，Laurikka J，Saraste A，et al.Cardiomyocyte apoptosis and ischemic preconditioning in open heart operations.Ann Thorac Surg，2003，76(2)：528-534.
42 Okubo S，Tanabe Y，Takeda K，et al.Ischemic preconditioning and morphine attenuate myocardial apoptosis and infarction after ischemia-reperfusion in rabbits：role of delta-opioid receptor.Am J Physiol Heart Circ Physiol，2004，287(4)：1786-1791.
作者点评：
IP结语 IP调动内源性保护机制，通过各种信号转导途径，进而触发信号分子事件的连锁反应，激活转录因子，介导保护性蛋白的基因表达从而降低细胞的氧化应激和炎症反应，提高心肌细胞自身对缺血、缺氧的耐受能力，为心肌保护提供了一个新的途径。随着对IP机制研究不断地深入及临床实施IP方法的不断改进，IP在心肌保护方面的效应将会更加明显。
